PL3456717T3 - Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej - Google Patents

Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej

Info

Publication number: PL3456717T3
Authority: PL; Poland
Prior art keywords: cot; diamino; quinoline; modulator; inflammatory disease
Prior art date: 2015-07-06

Application number

PL18186568T

Other languages

English (en)

Inventor

Elizabeth M. Bacon

Gayatri BALAN

Chien-Hung Chou

Christopher T. Clark

Jeromy J. Cottell

Musong Kim

Thorsten A. Kirschberg

John O. Link

Gary Phillips

Scott D. Schroeder

Neil H. Squires

Kirk L. Stevens

James G. Taylor

William J. Watkins

Nathan E. Wright

Sheila M. Zipfel

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-06-30

Publication date

2021-10-25

2016-06-30 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2021-10-25 Publication of PL3456717T3 publication Critical patent/PL3456717T3/pl

Links

WATPKLRWBYNCDK-UHFFFAOYSA-N 4,6-diaminoquinoline-3-carbonitrile Chemical class N1=CC(C#N)=C(N)C2=CC(N)=CC=C21 WATPKLRWBYNCDK-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
210000001685 thyroid gland Anatomy 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Obesity (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)

PL18186568T 2015-07-06 2016-06-30 Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej PL3456717T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562189158P	2015-07-06	2015-07-06
US201562269060P	2015-12-17	2015-12-17
PCT/US2016/040520 WO2017007689A1 (en)	2015-07-06	2016-06-30	Cot modulators and methods of use thereof
EP18186568.4A EP3456717B1 (en)	2015-07-06	2016-06-30	4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
EP16738976.6A EP3191470B1 (en)	2015-07-06	2016-06-30	Cot modulators and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3456717T3 true PL3456717T3 (pl)	2021-10-25

Family

ID=56411943

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL16738976T PL3191470T3 (pl)	2015-07-06	2016-06-30	Modulatory Cot i sposoby ich zastosowania
PL18186568T PL3456717T3 (pl)	2015-07-06	2016-06-30	Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL16738976T PL3191470T3 (pl)	2015-07-06	2016-06-30	Modulatory Cot i sposoby ich zastosowania

Country Status (40)

Country	Link
US (7)	US20170008905A1 (pl)
EP (3)	EP3456717B1 (pl)
JP (6)	JP6430060B2 (pl)
KR (5)	KR102073641B1 (pl)
CN (3)	CN109879859B (pl)
AU (5)	AU2016290820B2 (pl)
BR (1)	BR102016015656B1 (pl)
CA (1)	CA2971640C (pl)
CL (1)	CL2017003356A1 (pl)
CO (1)	CO2017013351A2 (pl)
CR (1)	CR20170599A (pl)
CU (1)	CU20170172A7 (pl)
CY (1)	CY1121750T1 (pl)
DK (1)	DK3191470T3 (pl)
DO (1)	DOP2017000311A (pl)
EA (1)	EA036788B1 (pl)
EC (1)	ECSP17084635A (pl)
ES (2)	ES2872076T3 (pl)
HR (1)	HRP20190853T1 (pl)
HU (1)	HUE043310T2 (pl)
IL (4)	IL293770B2 (pl)
LT (1)	LT3191470T (pl)
MA (1)	MA39422B1 (pl)
ME (1)	ME03425B (pl)
MX (1)	MX370984B (pl)
MY (1)	MY196173A (pl)
NZ (2)	NZ750707A (pl)
PE (1)	PE20180462A1 (pl)
PH (2)	PH12018500031A1 (pl)
PL (2)	PL3191470T3 (pl)
PT (2)	PT3191470T (pl)
RS (1)	RS58639B1 (pl)
SA (1)	SA517381350B1 (pl)
SG (1)	SG11201702041PA (pl)
SI (2)	SI3456717T1 (pl)
SV (1)	SV2017005605A (pl)
TW (3)	TWI699361B (pl)
UA (1)	UA123010C2 (pl)
UY (1)	UY36771A (pl)
WO (1)	WO2017007689A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
US10118890B2 (en)	2014-10-10	2018-11-06	The Research Foundation For The State University Of New York	Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
IL293770B2 (en)	2015-07-06	2023-07-01	Gilead Sciences Inc	Modulators of cot and methods of using them
KR20200022527A (ko)	2015-07-06	2020-03-03	길리애드 사이언시즈, 인코포레이티드	Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴
ES2800339T3 (es)	2016-06-30	2020-12-29	Gilead Sciences Inc	4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
HUE063811T2 (hu) *	2016-08-19	2024-02-28	Gilead Sciences Inc	HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
EA036921B1 (ru) *	2017-02-10	2021-01-15	Джилид Сайэнс, Инк.	Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) *	2017-04-26	2018-11-13	上海时莱生物技术有限公司	硼酸和硼酸酯类化合物及其制备方法和用途
TWI687415B (zh)	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
JPWO2019065516A1 (ja) *	2017-09-26	2020-09-10	日本曹達株式会社	キノリン化合物および農園芸用殺菌剤
WO2019161017A1 (en)	2018-02-15	2019-08-22	Gilead Sciences, Inc.	Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en)	2018-02-16	2020-06-30	Gilead Sciences, Inc.	Methods and intermediates for preparing therapeutic compounds
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) *	2018-03-23	2021-09-24	中国农业大学	一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) *	2018-06-25	2018-10-16	中国药科大学	一种氘代Fiduxosin的制备方法
WO2020018459A1 (en)	2018-07-16	2020-01-23	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
TWI770527B (zh)	2019-06-14	2022-07-11	美商基利科學股份有限公司	Cot 調節劑及其使用方法
US20220281855A1 (en)	2019-08-29	2022-09-08	Idorsia Pharmaceuticals Ltd	Alpha-d-galactopyranoside derivatives
TW202133846A (zh)	2019-11-26	2021-09-16	美商基利科學股份有限公司	預防hiv之蛋白殼抑制劑
JP2023520650A (ja) *	2020-03-30	2023-05-18	ギリアードサイエンシーズ，インコーポレイテッド	（Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
JP7446475B2 (ja) *	2020-04-02	2024-03-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｏｔ阻害剤化合物を調製するためのプロセス
CN115996925A (zh)	2020-06-25	2023-04-21	吉利德科学公司	用于治疗hiv的衣壳抑制剂
MX2023010241A (es)	2021-03-03	2023-09-12	Idorsia Pharmaceuticals Ltd	Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.
TW202304435A (zh) *	2021-06-04	2023-02-01	美商基利科學股份有限公司	治療ｎａｓｈ之方法
KR20240019340A (ko) *	2021-06-11	2024-02-14	뉴로내슨트, 아이엔씨.	헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물
US11787825B2 (en)	2021-12-03	2023-10-17	Gilead Sciences, Inc.	Therapeutic compounds for HIV virus infection

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3930837A (en)	1971-12-31	1976-01-06	Ici Australia Limited	3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4151298A (en)	1977-01-10	1979-04-24	Ciba-Geigy Corporation	Anthelmintic compositions
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja)	1988-07-26	1997-07-23	三井東圧化学株式会社	不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de)	1990-05-03	1991-11-07	Basf Ag	Cyanochinolinverbindungen
GB9310700D0 (en)	1993-05-24	1993-07-07	Zeneca Ltd	Novel composition
UA73073C2 (uk) *	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ503079A (en)	1997-08-28	2002-07-26	Nissan Chemical Ind Ltd	Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents
CA2336691C (en)	1998-07-10	2009-02-10	Massachusetts Institute Of Technology	Ligands for metals and metal-catalyzed processes
BR9914164A (pt)	1998-09-29	2001-06-26	American Cyanamid Co	Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
BR0308737A (pt)	2002-03-20	2005-01-11	Bristol Myers Squibb Co	Pró-drogas de fosfato de fluoroxindóis
RU2327689C2 (ru)	2003-03-03	2008-06-27	Ф.Хоффманн-Ля Рош Аг	2,5- замещенные тетрагидроизохинолины и фармацевтическая композиция для модуляции 5-нт6
BRPI0413667A (pt)	2003-08-19	2006-10-24	Wyeth Corp	Processo para a preparação de 4-amino-3-carbonitrilas de quinolina
US7399865B2 (en) *	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) *	2004-02-20	2005-09-16	Wyeth Corp	3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
CA2608540A1 (en) *	2005-05-18	2006-11-23	Wyeth	3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
CN101223170A (zh) *	2005-05-18	2008-07-16	惠氏公司	Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法
JP2009513659A (ja)	2005-10-28	2009-04-02	アボット・ラボラトリーズ	Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
MX2008012482A (es)	2006-03-31	2008-10-10	Abbott Lab	Compuestos de indazol.
DK2086960T3 (da)	2006-11-09	2014-06-10	Probiodrug Ag	Nye inhibitorer af glutaminylcyclase.
US8389544B2 (en)	2007-01-17	2013-03-05	The Hong Kong University Of Science And Technology	Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
GB0820856D0 (en)	2008-11-14	2008-12-24	Univ Leuven Kath	Novel inhibitors of flavivirus replication
TWI598347B (zh)	2009-07-13	2017-09-11	基利科學股份有限公司	調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) *	2009-12-22	2010-02-03	Imp Innovations Ltd	Compounds
CA2791247C (en)	2010-03-09	2019-05-14	Dana-Farber Cancer Institute, Inc.	Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
JP5730389B2 (ja) *	2010-06-09	2015-06-10	天津和美生物技術有限公司	シアノキノリン誘導体
EP2708540B1 (en)	2011-05-10	2018-07-25	Kyowa Hakko Kirin Co., Ltd.	Pyrimido-diazepinone compound
JP2014520776A (ja)	2011-07-04	2014-08-25	バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー	植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
RS54825B1 (sr)	2011-10-27	2016-10-31	Taisho Pharmaceutical Co Ltd	Derivati azola
LT3329919T (lt)	2011-11-11	2020-02-10	Gilead Apollo, Llc	Acc inhibitoriai ir jų panaudojimas
UY34573A (es)	2012-01-27	2013-06-28	Gilead Sciences Inc	Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh)	2012-06-13	2016-12-21	上海赛迦化工产品有限公司	多样性的手性氨基硼酸及其制备方法和应用
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103408572B (zh)	2013-07-12	2015-12-02	上海工程技术大学	手性氨基硼酸衍生物及其制备方法和应用
CN105814013A (zh)	2013-12-12	2016-07-27	卡利拉制药公司	双环烷基化合物及合成
CA2942144C (en)	2014-03-07	2023-08-22	Kalyra Pharmaceuticals, Inc.	Propellane derivates and synthesis
EP3166938A4 (en) *	2014-07-11	2018-01-17	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CN106999451B (zh)	2014-09-17	2021-04-02	里科瑞尔姆Ip控股有限责任公司	双环化合物
MX2017003933A (es)	2014-09-24	2017-06-30	Gilead Sciences Inc	Metodos de tratamiento de la enfermedad hepatica.
US9586933B2 (en)	2014-12-23	2017-03-07	Gilead Sciences, Inc.	Processes for preparing ASK1 inhibitors
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
EP3242722A4 (en)	2015-01-09	2018-07-11	Gilead Apollo, LLC	Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
KR20170102352A (ko)	2015-01-16	2017-09-08	쓰리엠 이노베이티브 프로퍼티즈 컴파니	그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법
KR20200022527A (ko)	2015-07-06	2020-03-03	길리애드 사이언시즈, 인코포레이티드	Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴
IL293770B2 (en)	2015-07-06	2023-07-01	Gilead Sciences Inc	Modulators of cot and methods of using them
JP6804540B2 (ja)	2015-12-31	2020-12-23	成都先導薬物開発股▲フン▼有限公司ＨｉｔｇｅｎＩｎｃ．	スルファミド誘導体およびその製造方法と応用
BR112018067408A2 (pt)	2016-03-02	2018-12-26	Gilead Apollo Llc	formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
WO2017221944A1 (ja)	2016-06-21	2017-12-28	パナソニックヘルスケアホールディングス株式会社	カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
ES2800339T3 (es)	2016-06-30	2020-12-29	Gilead Sciences Inc	4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
CN106512014A (zh)	2016-10-27	2017-03-22	武汉大学	肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR102424042B1 (ko)	2017-03-03	2022-07-22	길리애드 사이언시즈, 인코포레이티드	Acc 억제제 및 그의 고체 형태를 제조하는 방법
WO2018183193A1 (en)	2017-03-28	2018-10-04	Gilead Sciences, Inc.	Therapeutic combinations for treating liver diseases
CN110520125A (zh)	2017-04-12	2019-11-29	吉利德科学公司	治疗肝病的方法
KR20220103807A (ko)	2017-10-06	2022-07-22	길리애드 사이언시즈, 인코포레이티드	Acc 억제제를 포함하는 조합 요법
JP2022519906A (ja)	2019-02-19	2022-03-25	ギリアードサイエンシーズ，インコーポレイテッド	Ｆｘｒアゴニストの固体形態
EP3934615A4 (en)	2019-03-08	2023-01-25	The Regents Of The University Of California	COMPOSITIONS AND METHODS FOR TREATMENT OF ACNE
TWI770527B (zh)	2019-06-14	2022-07-11	美商基利科學股份有限公司	Cot 調節劑及其使用方法
AR119594A1 (es)	2019-08-09	2021-12-29	Gilead Sciences Inc	Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP2023520650A (ja)	2020-03-30	2023-05-18	ギリアードサイエンシーズ，インコーポレイテッド	（Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
JP7446475B2 (ja)	2020-04-02	2024-03-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｏｔ阻害剤化合物を調製するためのプロセス
TW202304435A (zh)	2021-06-04	2023-02-01	美商基利科學股份有限公司	治療ｎａｓｈ之方法

2016
- 2016-06-30 IL IL293770A patent/IL293770B2/en unknown
- 2016-06-30 JP JP2018500585A patent/JP6430060B2/ja active Active
- 2016-06-30 CU CUP2017000172A patent/CU20170172A7/xx unknown
- 2016-06-30 PT PT16738976T patent/PT3191470T/pt unknown
- 2016-06-30 SI SI201631197T patent/SI3456717T1/sl unknown
- 2016-06-30 AU AU2016290820A patent/AU2016290820B2/en active Active
- 2016-06-30 NZ NZ750707A patent/NZ750707A/en unknown
- 2016-06-30 PE PE2017002804A patent/PE20180462A1/es unknown
- 2016-06-30 EA EA201792613A patent/EA036788B1/ru unknown
- 2016-06-30 MA MA39422A patent/MA39422B1/fr unknown
- 2016-06-30 KR KR1020197011792A patent/KR102073641B1/ko active IP Right Grant
- 2016-06-30 RS RS20190498A patent/RS58639B1/sr unknown
- 2016-06-30 EP EP18186568.4A patent/EP3456717B1/en active Active
- 2016-06-30 LT LTEP16738976.6T patent/LT3191470T/lt unknown
- 2016-06-30 PT PT181865684T patent/PT3456717T/pt unknown
- 2016-06-30 UA UAA201712984A patent/UA123010C2/uk unknown
- 2016-06-30 EP EP21162393.9A patent/EP3896064A1/en active Pending
- 2016-06-30 NZ NZ738525A patent/NZ738525A/en unknown
- 2016-06-30 ES ES18186568T patent/ES2872076T3/es active Active
- 2016-06-30 KR KR1020187003221A patent/KR101974793B1/ko active IP Right Grant
- 2016-06-30 CN CN201910292757.5A patent/CN109879859B/zh active Active
- 2016-06-30 HU HUE16738976A patent/HUE043310T2/hu unknown
- 2016-06-30 CN CN202210008753.1A patent/CN114380799A/zh active Pending
- 2016-06-30 WO PCT/US2016/040520 patent/WO2017007689A1/en active Application Filing
- 2016-06-30 PL PL16738976T patent/PL3191470T3/pl unknown
- 2016-06-30 EP EP16738976.6A patent/EP3191470B1/en active Active
- 2016-06-30 KR KR1020227031078A patent/KR20220129667A/ko not_active Application Discontinuation
- 2016-06-30 DK DK16738976.6T patent/DK3191470T3/en active
- 2016-06-30 CN CN201680050602.5A patent/CN107922390B/zh active Active
- 2016-06-30 CA CA2971640A patent/CA2971640C/en active Active
- 2016-06-30 ES ES16738976T patent/ES2734713T3/es active Active
- 2016-06-30 KR KR1020207002878A patent/KR102443575B1/ko active IP Right Grant
- 2016-06-30 SI SI201630202T patent/SI3191470T1/sl unknown
- 2016-06-30 IL IL274568A patent/IL274568B/en unknown
- 2016-06-30 ME MEP-2019-117A patent/ME03425B/me unknown
- 2016-06-30 MX MX2017004737A patent/MX370984B/es active IP Right Grant
- 2016-06-30 SG SG11201702041PA patent/SG11201702041PA/en unknown
- 2016-06-30 CR CR20170599A patent/CR20170599A/es unknown
- 2016-06-30 KR KR1020247000058A patent/KR20240008398A/ko not_active Application Discontinuation
- 2016-06-30 PL PL18186568T patent/PL3456717T3/pl unknown
- 2016-06-30 MY MYPI2018700007A patent/MY196173A/en unknown
- 2016-06-30 US US15/199,534 patent/US20170008905A1/en not_active Abandoned
- 2016-07-04 BR BR102016015656-4A patent/BR102016015656B1/pt active Search and Examination
- 2016-07-05 TW TW107117905A patent/TWI699361B/zh active
- 2016-07-05 TW TW105121281A patent/TWI634112B/zh active
- 2016-07-05 TW TW109122003A patent/TWI748539B/zh active
- 2016-07-06 UY UY0001036771A patent/UY36771A/es not_active Application Discontinuation
2017
- 2017-02-09 US US15/429,086 patent/US9878995B2/en active Active
- 2017-04-18 SA SA517381350A patent/SA517381350B1/ar unknown
- 2017-12-20 IL IL256433A patent/IL256433B/en active IP Right Grant
- 2017-12-22 CO CONC2017/0013351A patent/CO2017013351A2/es unknown
- 2017-12-22 CL CL2017003356A patent/CL2017003356A1/es unknown
- 2017-12-22 SV SV2017005605A patent/SV2017005605A/es unknown
- 2017-12-22 EC ECIEPI201784635A patent/ECSP17084635A/es unknown
- 2017-12-26 DO DO2017000311A patent/DOP2017000311A/es unknown
2018
- 2018-01-03 PH PH12018500031A patent/PH12018500031A1/en unknown
- 2018-02-07 US US15/891,163 patent/US20180237455A1/en not_active Abandoned
- 2018-09-13 JP JP2018171794A patent/JP6781221B2/ja active Active
2019
- 2019-04-23 US US16/391,673 patent/US20190248807A1/en not_active Abandoned
- 2019-05-03 AU AU2019203122A patent/AU2019203122B2/en active Active
- 2019-05-08 HR HRP20190853TT patent/HRP20190853T1/hr unknown
- 2019-05-20 CY CY20191100535T patent/CY1121750T1/el unknown
- 2019-05-29 IL IL266995A patent/IL266995B/en active IP Right Grant
- 2019-07-26 JP JP2019137759A patent/JP6906021B2/ja active Active
- 2019-12-17 US US16/717,074 patent/US11066414B2/en active Active
2020
- 2020-09-06 PH PH12020551397A patent/PH12020551397A1/en unknown
- 2020-10-20 AU AU2020257055A patent/AU2020257055B2/en active Active
- 2020-12-16 JP JP2020208330A patent/JP7138155B2/ja active Active
2021
- 2021-05-11 US US17/317,041 patent/US11905299B2/en active Active
2022
- 2022-04-11 JP JP2022065168A patent/JP2022082816A/ja not_active Withdrawn
- 2022-06-10 AU AU2022204050A patent/AU2022204050B2/en active Active
2023
- 2023-12-11 US US18/534,800 patent/US20240254137A1/en active Pending
2024
- 2024-05-17 JP JP2024081151A patent/JP2024100865A/ja active Pending
- 2024-07-17 AU AU2024204902A patent/AU2024204902A1/en active Pending

Also Published As

Publication number	Publication date
HRP20190853T1 (hr)	2019-06-28
CN109879859A (zh)	2019-06-14
IL293770B2 (en)	2023-07-01
EP3456717B1 (en)	2021-03-17
EP3456717A1 (en)	2019-03-20
US9878995B2 (en)	2018-01-30
IL256433B (en)	2019-06-30
WO2017007689A1 (en)	2017-01-12
ME03425B (me)	2020-01-20
AU2020257055B2 (en)	2022-03-31
CO2017013351A2 (es)	2018-05-21
PH12018500031B1 (en)	2018-07-09
US20240254137A1 (en)	2024-08-01
AU2022204050B2 (en)	2024-04-18
PE20180462A1 (es)	2018-03-06
SA517381350B1 (ar)	2021-03-11
MA39422A (fr)	2017-07-19
AU2020257055A1 (en)	2020-11-12
KR20180022982A (ko)	2018-03-06
KR102073641B1 (ko)	2020-02-05
CN107922390B (zh)	2019-05-10
JP2018193405A (ja)	2018-12-06
TW201712005A (zh)	2017-04-01
PH12020551397A1 (en)	2021-08-16
JP6781221B2 (ja)	2020-11-04
AU2022204050A1 (en)	2022-06-30
CA2971640A1 (en)	2017-01-12
CL2017003356A1 (es)	2018-07-06
IL293770B1 (en)	2023-03-01
IL266995A (en)	2019-07-31
ES2872076T3 (es)	2021-11-02
US20190248807A1 (en)	2019-08-15
TW202114673A (zh)	2021-04-16
KR20190045416A (ko)	2019-05-02
CY1121750T1 (el)	2020-07-31
CN114380799A (zh)	2022-04-22
US20180237455A1 (en)	2018-08-23
AU2024204902A1 (en)	2024-08-01
US20170152240A1 (en)	2017-06-01
RS58639B1 (sr)	2019-05-31
AU2016290820B2 (en)	2019-03-07
PT3191470T (pt)	2019-06-05
SI3191470T1 (sl)	2019-04-30
TWI634112B (zh)	2018-09-01
JP2019178178A (ja)	2019-10-17
US11066414B2 (en)	2021-07-20
DOP2017000311A (es)	2018-01-15
IL256433A (en)	2018-02-28
HUE043310T2 (hu)	2019-08-28
MA39422B1 (fr)	2019-03-29
PH12018500031A1 (en)	2018-07-09
SI3456717T1 (sl)	2021-08-31
US20200123172A1 (en)	2020-04-23
MX370984B (es)	2020-01-09
CU20170172A7 (es)	2018-06-05
MY196173A (en)	2023-03-17
PT3456717T (pt)	2021-05-26
US11905299B2 (en)	2024-02-20
NZ738525A (en)	2019-03-29
SG11201702041PA (en)	2017-04-27
IL266995B (en)	2020-05-31
EP3896064A1 (en)	2021-10-20
MX2017004737A (es)	2017-06-19
US20230002407A1 (en)	2023-01-05
KR101974793B1 (ko)	2019-05-02
AU2019203122A1 (en)	2019-05-30
SV2017005605A (es)	2018-07-18
LT3191470T (lt)	2019-05-10
NZ750707A (en)	2023-09-29
JP7138155B2 (ja)	2022-09-15
TWI699361B (zh)	2020-07-21
CN107922390A (zh)	2018-04-17
EA201792613A1 (ru)	2018-06-29
AU2016290820A1 (en)	2018-01-18
EA036788B1 (ru)	2020-12-21
BR102016015656B1 (pt)	2021-11-03
IL274568A (en)	2020-06-30
UY36771A (es)	2017-01-31
EP3191470A1 (en)	2017-07-19
IL293770A (en)	2022-08-01
KR20220129667A (ko)	2022-09-23
BR102016015656A2 (pt)	2020-09-24
JP2024100865A (ja)	2024-07-26
TWI748539B (zh)	2021-12-01
IL274568B (en)	2022-07-01
JP2018520161A (ja)	2018-07-26
CR20170599A (es)	2018-02-28
PL3191470T3 (pl)	2019-08-30
ECSP17084635A (es)	2018-01-31
AU2019203122B2 (en)	2020-10-01
JP6430060B2 (ja)	2018-11-28
CA2971640C (en)	2020-09-22
DK3191470T3 (en)	2019-04-15
TW201908305A (zh)	2019-03-01
JP6906021B2 (ja)	2021-07-21
KR20240008398A (ko)	2024-01-18
UA123010C2 (uk)	2021-02-03
CN109879859B (zh)	2022-01-25
ES2734713T3 (es)	2019-12-11
US20170008905A1 (en)	2017-01-12
JP2022082816A (ja)	2022-06-02
KR102443575B1 (ko)	2022-09-16
JP2021042252A (ja)	2021-03-18
EP3191470B1 (en)	2019-02-27
KR20200013120A (ko)	2020-02-05

Publication	Publication Date	Title
SI3456717T1 (sl)	2021-08-31	4,6-diamino-kinolin-3-karbonitrilni derivat kot modulator cancer osaka thyroid (COT) za zdravljenje vnetne bolezni
HK1257818A1 (zh)	2019-11-01	用於治療炎症相關病症的局部藥物製劑
HK1244280B (zh)	2020-05-15	用於治療感染性疾病的吡嗪化合物
IL263538A (en)	2019-01-31	Radio-pharmaceutical complexes
IL252053A0 (en)	2017-07-31	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
HK1257665A1 (zh)	2019-10-25	用於治療線粒體疾病的新化合物
SG11201608764QA (en)	2016-11-29	Novel disubstituted 1, 2, 4-triazine compound
HK1248226A1 (zh)	2018-10-12	1，4二取代的咪唑衍生物
ZA201706402B (en)	2019-01-30	C.novyi for the treatment of solid tumors in humans
EA201792612A1 (ru)	2018-07-31	6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
NZ735250A (en)	2020-08-28	Pyrrolidine carboxamido derivatives and methods for preparing and using the same
SI3449135T1 (sl)	2022-04-29	Dvojni konektor za povezovanje dveh komponent
GB201721287D0 (en)	2018-01-31	Treatment for inflammatory disease
EP3275450A4 (en)	2018-11-14	Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3268046A4 (en)	2018-11-21	Conjugates for treating diseases
SG11201803584RA (en)	2018-05-30	1,4-dicarbonyl-piperidyl derivatives
IL244393A0 (en)	2016-04-21	A new derivative of 6,2-diaminopyrimidine
HK1254800A1 (zh)	2019-07-26	2，3，4，5-四氫吡啶-6-胺衍生物
IL261329B (en)	2021-04-29	Radioactive drug complexes
HK1232121A1 (zh)	2018-01-05	作為抗氧化治療的富勒烯化合物
EP3273974A4 (en)	2018-11-07	Therapy for malignant disease
IL261958A (en)	2018-10-31	Formulations for treating constipation
IL243133B (en)	2018-07-31	Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
HK1256371A1 (zh)	2019-09-20	用於治療腫瘤的方法
EP3354271A4 (en)	2018-12-26	Agent for treating arthrological diseases